Xenon Pharmaceuticals Inc.

Epilepsy and Seizure Disorders

Clinical research is centered on focal epilepsy, including adult focal (partial onset) epilepsy and focal-onset seizures, with additional attention to primary generalized tonic-clonic seizures.

  • Focal-onset seizures
  • Adult focal epilepsy
  • Primary generalized tonic-clonic seizures

These studies reflect sustained interest in seizure reduction and symptom control across multiple forms of epilepsy.

Major Depressive Disorder

The sponsor also funds research in major depressive disorder, focusing on treatment options for depressive symptoms and overall mood improvement.

  • Major depressive disorder
  • Depressive symptoms

This area extends the company’s interest in central nervous system conditions beyond seizure-related disease.

Bipolar Depression

Another active therapeutic area is bipolar depression, including depressive episodes associated with bipolar I or II disorder.

  • Bipolar I disorder
  • Bipolar II disorder
  • Depressive episodes

Research in this domain addresses mood disorder management within the broader spectrum of affective disorders.

Neurology and Central Nervous System Therapeutics

The overall pipeline is strongly oriented toward neurology, with overlapping programs in seizure control and mood disorders that fall within central nervous system therapeutics.

  • Neurology
  • Central nervous system disorders
  • Seizure control
  • Mood disorders

Research activity spans multiple countries and sites, supporting development efforts in both epilepsy and psychiatric indications.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A study of azetukalner compared to placebo for adults with moderate-to-severe major depressive disorder

    Recruiting

    3 1
    Investigated drugs:
    Czechia Finland Germany Poland Romania Slovakia +1
  • A study to evaluate the effectiveness and safety of azetukalner in patients experiencing depressive episodes associated with bipolar disorder.

    Recruiting

    3 1
    Investigated drugs:
    Bulgaria Germany Poland Spain
  • Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

    Recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Finland +10
  • Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

    Recruiting

    3 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Finland +8
  • Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia France +6
  • A study to evaluate the safety and effectiveness of azetukalner in patients with bipolar depression

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Bulgaria France Germany Spain